佐力药业9月9日获融资买入3749.33万元，融资余额6.03亿元

Core Viewpoint - Zhaoli Pharmaceutical experienced a 2.01% decline in stock price on September 9, with a trading volume of 276 million yuan, indicating potential market volatility and investor sentiment shifts [1]. Financing and Margin Trading - On September 9, Zhaoli Pharmaceutical had a financing purchase amount of 37.49 million yuan and a financing repayment of 34.69 million yuan, resulting in a net financing purchase of 2.80 million yuan [1]. - The total margin trading balance for Zhaoli Pharmaceutical reached 605 million yuan, with the financing balance accounting for 4.65% of the circulating market value, indicating a high level of leverage compared to the past year [1]. - The company had a margin loan repayment of 2,100 shares and a short sale of 700 shares on the same day, with a short sale amounting to 12,900 yuan [1]. Company Overview - Zhaoli Pharmaceutical, established on January 28, 2000, and listed on February 22, 2011, is located in Deqing County, Zhejiang Province. The company specializes in the research, production, and sales of medicinal fungi products, traditional Chinese medicine pieces, and formula granules [1]. - The revenue composition of Zhaoli Pharmaceutical includes: 56.07% from the medicinal fungi series, 21.85% from traditional Chinese medicine pieces, 10.11% from other products, 7.08% from the Bailin series, 4.62% from formula granules, and 0.26% from other supplementary products [1]. Financial Performance - As of June 30, Zhaoli Pharmaceutical reported a total of 38,600 shareholders, an increase of 0.92% from the previous period, with an average of 15,627 circulating shares per person, a decrease of 0.91% [2]. - For the first half of 2025, Zhaoli Pharmaceutical achieved a revenue of 1.599 billion yuan, representing a year-on-year growth of 11.99%, and a net profit attributable to shareholders of 374 million yuan, reflecting a growth of 26.16% [2]. Dividend Distribution - Since its A-share listing, Zhaoli Pharmaceutical has distributed a total of 1.442 billion yuan in dividends, with 942 million yuan distributed over the past three years [3]. Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders of Zhaoli Pharmaceutical, new entrants include China Europe Responsibility Investment Mixed A (009872) with 6.578 million shares, and Innovation Medicine (159992) with 6.574 million shares. South China CSI 1000 ETF (512100) also entered the top ten with 6.476 million shares [3].